Publication | Open Access

SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer

Breast OncologyOncologyPhase IiSolti NeoparpPathologyBreast CancerTriple-negative Breast CancerCancer TreatmentMedicineRadiation Oncology